b) isolating on a solid phase a specified fraction of the amount of receptor contacted with the analyte, including analyte/receptor complex and unreacted receptor,

c) detecting the amount of analyte/receptor complex in said isolated specified fraction, and

d) from the detected amount of analyte/receptor complex, determining the concentration of analyte in the sample.

4. (Amended) The method according to claim 1 or 2, wherein isolating said specified fraction of the amount of receptor contacted with the sample on the solid phase comprises providing a solid phase having binding sites for the receptor, and after contacting the sample, or an aliquot thereof, with a liquid phase containing the receptor, binding said specified fraction of receptor to the solid phase.

7. (Amended) The method according to claim 1 or 2, wherein isolating said specified fraction of the amount of receptor on the solid phase comprises contacting the sample with a specified amount of receptor, a specified fraction of which amount is immobilized to said solid phase and the remaining amount of receptor being in a liquid phase.

8. (Amended) ~~The~~ method according to claim 1, wherein in step c) the analyte/receptor complex is ~~detected~~ by a labeled detection reagent which binds specifically to the analyte.

10. The method according to claim 1, wherein in step c) the analyte/receptor complex is detected by a labelled detection reagent which binds specifically to the analyte.

11. (Amended) The method according to claim 1, wherein the ratio between said isolated fraction of the ~~amount of active analyte-binding~~ receptor and the ~~total amount of active analyte-binding~~ receptor contacted with the sample is in the range of from about 1:2 to about 1:1000.

12. (Amended) The method according to claim 1, wherein said solid phase binding sites for the receptor are immobilized in a reaction zone of flow matrix.

13. (Amended) The method according to claim 1, wherein the receptor is an antibody or immunoreactive fragment thereof.

14. (Amended) The method according to claim 8, wherein the detection reagent is an antibody or immunoreactive fragment thereof.

15. (Amended) The method according to claim 8, wherein the detection reagent is labelled by a fluorophore or chromophore.

B4 Subt R8

16. (Amended) ~~The method~~ according to claim 7, wherein the specific binding pair is biotin-avidin or ~~biotin-strepavidin~~.

17. (Amended) The method according to claim 1, wherein the sample is an undiluted serum sample.

18. (Amended) The method according to claim 1, wherein the sample is an undiluted whole blood sample.

Subt C10 B5

20. (Amended) The test kit according to claim 19, wherein the ratio between the receptor-binding capacity of ligand immobilized on the solid phase and the ligand-binding capacity of the analyte-specific receptor substance is in the range of from about 1:2 to about 1:1000.

21. (Amended) The test kit according to claim 19 or 20, further comprising a lateral flow membrane strip having said receptor-binding ligand immobilized in or on a reaction zone of the membrane and having said analyte-binding receptor substance dissolvably pre-deposited in or on the membrane upstream of the reaction zone.

23. (Amended) The test kit according to claim 22, wherein the ratio between the amount of ligand-binding analyte-specific receptor and the total amount of analyte-specific receptor is in the range of from about 1:2 to about 1:1000.

24. (Amended) The test kit according to claim 22 or 23, further comprising a lateral flow membrane strip having said receptor-binding ligand immobilized in or on a reaction zone of the membrane and having said analyte-binding receptor substance dissolvably pre-deposited in or on the membrane upstream of the reaction zone.

26. (Amended) The test kit according to claim 25, wherein the ratio between said second amount of analyte-binding receptor substance immobilized to the solid phase, and the sum of said first

Please add the following new claims.

--29. The method according to claim 9, wherein the ratio between said isolated fraction of the amount of active analyte-binding receptor and the total amount of active analyte-binding receptor contacted with the sample is in the range of from about 1:5 to 1:100.

30. The method according to claim 9, wherein the ratio between said isolated fraction of the amount of active analyte-binding receptor and the total amount of active analyte-binding receptor contacted with the sample is no more than about 1:20.

31. The method according to claim 10, wherein said flow matrix is a lateral flow matrix.

32. The method according to claim 29, wherein said lateral flow matrix is a membrane strip.

33. The test kit according to claim 20, wherein the ratio between the receptor-binding capacity of ligand immobilized on the

solid phase and the ligand-binding capacity of the analyte-specific receptor substance is in the range of from about 1:5 to 1:100.

34. The test kit according to claim 20, wherein the ratio between the receptor-binding capacity of ligand immobilized on the solid phase and the ligand-binding capacity of the analyte-specific receptor substance is no more than about 1:20.

35. The test kit according to claim 23, wherein the ratio between the amount of ligand-binding analyte-specific receptor and the total amount of analyte-specific receptor is in the range of from about 1:5 to 1:100.

36. The test kit according to claim 23, wherein the ratio between the amount of ligand-binding analyte-specific receptor and the total amount of analyte-specific receptor is no more than about 1:20.

37. The test kit according to claim 26, wherein the ratio between said second amount of analyte-binding receptor substance immobilized to the solid phase, and the sum of said first and second amounts of analyte-binding receptor substance is in the range of from about 1:5 to 1:100.

B8

D13 cont

38. The test kit according to claim 26, wherein the ratio between said second amount of analyte-binding receptor substance immobilized to the solid phase, and the sum of said first and second amounts of analyte-binding receptor substance is no more than about 1:20.--

Docket 1614-0254P